Risk assessment for the development of hepatocellular carcinoma: According to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease

Journal of Hepatology

Volumn 53, Issue 1, 2010, Pages 118-125

  Eun, Jong Ryul ^a   Lee, Heon Ju ^a   Kim, Tae Nyeun ^a   Lee, Kyeung Soo ^a  

^a Yeungnam University College of Medicine   (South Korea)

Author keywords

Chronic hepatitis B; Hepatocellular carcinoma; Lamivudine; Prevention; Sustained viral suppression

Indexed keywords

HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; VIRUS DNA; ANTIVIRUS AGENT;

ADULT; ARTICLE; CANCER INCIDENCE; CANCER RISK; CARCINOGENESIS; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT RESPONSE; BLOOD; CARCINOMA, HEPATOCELLULAR; CASE CONTROL STUDY; CLASSIFICATION; COMPLICATION; DRUG EFFECTS; GENETICS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; ISOLATION AND PURIFICATION; LIVER NEOPLASMS; MIDDLE AGED; MUTATION; TIME; VIROLOGY; YOUNG ADULT;

ADULT; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; DNA, VIRAL; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MUTATION; RETROSPECTIVE STUDIES; RISK ASSESSMENT; TIME FACTORS; YOUNG ADULT;

EID: 77953119545     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2010.02.026     Document Type: Article

References (30)

1. Llovet J.M., Burroughs A., and Bruix J. Hepatocellular carcinoma. Lancet 362 (2003) 1907-1917
2. El-Serag H.B., and Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132 (2007) 2557-2576
3. Korea National Statistical Office. Annual report on the cause of death statistics; 2006.
4. Ohata K., Hamasaki K., Toriyama K., Ishikawa H., Nakao K., and Eguchi K. High viral load is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Gastroenterol Hepatol 19 (2004) 670-675
5. Ishikawa T., Ichida T., Yamagiwa S., Sugahara S., Uehara K., Okoshi S., et al. High viral loads, serum alanine aminotransferase and gender are predictive factors for the development of hepatocellular carcinoma from viral compensated liver cirrhosis. J Gastroenterol Hepatol 16 (2001) 1274-1281
6. Chen C.J., Yang H.Y., Su J., Jen C.L., You S.L., Lu S.N., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295 (2006) 65-73
7. Kim B.K., Park J.Y., Kim D.Y., Kim J.K., Kim K.S., Choi J.S., et al. Persistent hepatitis B viral replication affects recurrence of hepatocellular carcinoma after curative resection. Liver Int 28 (2008) 393-401
8. Wu J.C., Huang Y.H., Chau G.Y., Su C.W., Lai C.R., Lee P.C., et al. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol 51 (2009) 890-897
9. Leung N. Recent data on treatment of chronic hepatitis B with nucleos(t)ide analogues. Hepatol Int 2 (2008) 163-178
10. Hann H.W. Active antiviral therapy for chronic hepatitis B and hepatocellular carcinoma. Minerva Gastroenterol Dietol 54 (2008) 19-30
11. Liaw Y.F., Sung J.J., Chow W.C., Farrell G., Lee C.Z., Yuen H., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351 (2004) 1521-1531
12. Matsumoto A., Tanaka E., Rokuhara A., Kiyosawa K., Kumada H., Omata M., et al. Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: a multicenter retrospective study of 2795 patients. Hepatol Res 32 (2005) 173-184
13. Lee H.J., Eun J.R., Jang B.I., and Kim T.N. Prevention by lamivudine of hepatocellular carcinoma in patients with hepatitis B virus. Gut Liver 1 (2007) 151-158
14. Piao C.Y., Fujioka S., Iwasaki Y., Fujio K., Kaneyoshi T., Araki Y., et al. Lamivudine treatment in patients with HBV-related hepatocellular carcinoma-using an untreated, matched control cohort. Acta Med Okayama 59 (2005) 217-224
15. Yuen M.F., Chow D.H., Tsui K., Wong B.C., Yuen J.C., Wong D.K., et al. Liver histology of Asian patients with chronic hepatitis B on prolonged lamivudine therapy. Aliment Pharmacol Ther 21 (2005) 841-849
16. Dienstag J.L., Goldin R.D., Heathcote E.J., Hann H.W., Woessner M., Stephenson S.L., et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 124 (2003) 105-117
17. Hache C., and Villeneuve J.P. Lamivudine treatment in patients with chronic hepatitis B and cirrhosis. Expert Opin Pharmacother 7 (2006) 1835-1843
18. Infante-Rivard C., Esnaola S., and Villeneuve J.P. Clinical and statistical validity of conventional prognostic factors in predicting short-term survival among cirrhotics. Hepatology 7 (1987) 660-664
19. Available from: http://www.klcsg.or.kr.
20. Andreone P., Cramenzi A., Cursaro C., Biselli M., Camma C., Trevisani F., et al. High risk of hepatocellular carcinoma in anti-HBe positive liver cirrhosis patients developing lamivudine resistance. J Viral Hepat 11 (2004) 439-442
21. Fattovich G., Stroffolini T., Zagni I., and Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 127 (2004) S35-S50
22. Fattovich G., Pantalena M., Zagni I., Realdi G., Schalm S.W., and Christensen E. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol 97 (2002) 2886-2895
23. Chiaramonte M., Stroffolini T., Vian A., Stazi M.A., Floreani A., Lorenzoni U., et al. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. Cancer 85 (1999) 2132-2137
24. Kato Y., Nakata K., Omagari K., Furukawa R., Kusumoto Y., Mori I., et al. Risk of hepatocellular carcinoma in patients with cirrhosis in Japan. Analysis of infectious hepatitis viruses. Cancer 74 (1994) 2234-2238
25. Beasley R.P. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 61 (1988) 1942-1956
26. Brechot C., Gozuacik D., Murakami Y., and Paterlini-Brechot P. Molecular bases for the development of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Semin Cancer Biol 10 (2000) 211-231
27. Koike K., Tsutsumi T., Fujie H., Shintani Y., and Kyoji M. Molecular mechanism of viral hepatocarcinogenesis. Oncology 621 (2002) S29-S37
28. Chisari F.V., Klopchin K., Moriyama T., Pasquinelli C., Dunsford H.A., Sell S., et al. Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell 59 (1989) 1145-1156
29. Moradpour D., and Wands J.R. The molecular pathogenesis of hepatocellular carcinoma. J Viral Hepat 1 (1994) 17-31
30. Hosaka T., Suzuki F., Kobayashi M., Hirakawa M., Kawamura Y., Yastuju H., et al. Development of HCC in patients receiving adefovir dipivoxil for lamivudine-resistant hepatitis B virus mutants. Hepatol Res (2009) [Epub ahead of print]